Loretta J. Nastoupil, MD, MD Anderson Cancer Center

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

ByGina Mauro,Sandy Wong, MD,Neal Shore, MD, FACS,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Evolving Therapies in R/R DLBCL: Concluding Remarks

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

Treating Primary Refractory DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

Bridging Therapy in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

R/R DLBCL: Transplants in the Era of CAR-T

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Safety/Tolerability

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Understanding the CAR-T Process: Collection Through Infusion

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Treating R/R DLBCL With CAR-T: Current Barriers

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

CAR-T Treatment Options for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

CAR T-Cell Therapy for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

Novel Therapies for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

Tafasitamab Combined With Lenalidomide in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

R/R DLBCL: Second-Line Treatment Options

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

DLBCL: Treatment Considerations for Challenging Populations

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

DLBCL: Circumstances for Deviating Away From R-CHOP

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Developing CAR T-Cell Trials

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Allogenic CAR T-Cell Therapy in Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy’s Future for Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T Cells and Lymphoma Adverse Events

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

LBCL Therapy: The Right Therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

R/R NHL: Candidate Identification and Referrals

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy for Follicular Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

LDH and ECOG Performance Tests

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Articles by Loretta J. Nastoupil, MD, MD Anderson Cancer Center

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

Evolving Therapies in R/R DLBCL: Concluding Remarks

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

R/R DLBCL: Novel Therapies in the Pipeline

Treating Primary Refractory DLBCL

Bridging Therapy in R/R DLBCL

R/R DLBCL: Transplants in the Era of CAR-T

CAR T for R/R DLBCL: Improving Access and Utilization

CAR T for R/R DLBCL: Safety/Tolerability

Understanding the CAR-T Process: Collection Through Infusion

Treating R/R DLBCL With CAR-T: Current Barriers

CAR-T Treatment Options for R/R DLBCL

CAR T-Cell Therapy for R/R DLBCL

Novel Therapies for R/R DLBCL

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

Tafasitamab Combined With Lenalidomide in R/R DLBCL

R/R DLBCL: Second-Line Treatment Options

DLBCL: Treating Patients Following Relapse on Frontline Therapy

DLBCL: Treatment Considerations for Challenging Populations

DLBCL: Circumstances for Deviating Away From R-CHOP

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

Developing CAR T-Cell Trials

Allogenic CAR T-Cell Therapy in Lymphoma

CAR T-Cell Therapy’s Future for Lymphoma

CAR T Cells and Lymphoma Adverse Events

LBCL Therapy: The Right Therapy

R/R NHL: Candidate Identification and Referrals

CAR T-Cell Therapy for Follicular Lymphoma

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

LDH and ECOG Performance Tests

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma